Articles tagged with Oncology
A study found that blood cancer survivors are more likely to face financial hardship and take fewer medications due to high-cost immunotherapy treatments. Financial strain affects both Medicare-insured and uninsured patients, highlighting the need for better financial support and policy strategies.
The American Society for Radiation Oncology (ASTRO) will host its 67th Annual Meeting in San Francisco from September 27 to October 1, 2025. The meeting will feature over 2,500 research presentations and posters on advances in radiation oncology and non-cancer indications.
A study by Mass General Brigham found that patients with glioblastoma who received gabapentin lived longer than those who didn't. The medication was shown to confer a four-month survival benefit, with patients on gabapentin surviving an average of 16 months compared to 12 months for those without the drug.
A cohort study found that long-term survival was similar among patients with low-risk early-stage cervical carcinoma who underwent simple, modified, or radical hysterectomy. These findings support the use of simple hysterectomy in select patients.
Researchers at the University of Chicago Medicine discovered a new phenomenon where high doses of radiation cause growth in existing metastatic tumors. The 'badscopal effect' is attributed to increased production of amphiregulin, which weakens the immune system and makes cancer cells more resistant.
Researchers identified changes in stromal tissue associated with increased aggressive breast cancer risk and poorer survival rates among women with benign breast disease. The study used machine learning to detect subtle changes in breast tissue samples from over 9,000 women.
A new study uses explainable machine learning to predict metastasis and mortality in children with medulloblastoma, identifying key immune factors driving risk. The model provides a transparent approach to prognostic accuracy and supports personalized clinical decision-making.
City of Hope's largest outpatient facility, Hope Plaza, brings together cancer experts for highly individualized care. The center offers cutting-edge technologies, over 735 clinical trials, and integrated supportive services.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
A large-scale study published in eClinicalMedicine found that transmasculine and gender-diverse individuals who use testosterone for an average of five years do not have an increased risk of gynecological cancer. The research, which followed 1955 participants, suggests that hormone therapy may be safe for this group.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
City of Hope experts will present new cancer treatment approaches, targeted therapies and lifestyle changes aimed at reducing cancer risk and improving survival. Highlights include discussions on biomarkers in kidney cancer, symptom science and palliative care.
Abnormal fungal colonization in pancreatic ductal adenocarcinoma (PDA) promotes tumor growth and activates the host complement system, suggesting Malassezia as a potential driver of cancer development.
The NCCN Policy Summit brought together experts to discuss ways to strengthen collaborative cancer care, from early detection to survivorship. Key findings include the need for better communication and coordination between primary care and oncology providers.
A new study published in the Journal of the National Cancer Institute suggests that artificial intelligence can help detect interval breast cancers earlier, potentially reducing their rates by 30%. The research used AI software to analyze mammograms and identify subtle signs of cancer that were missed by radiologists.
A new study introduces the RAPID-RT study, which uses a rapid-learning approach to evaluate the impact of treatment modifications in radiotherapy. The technique aims to reduce cardiac toxicity and improve survival in lung cancer patients by minimising dose to the top of the heart, a previously identified risk area.
Pennington Biomedical welcomes Dr. Adithya Hari, MD, with expertise in nuclear oncology and translational science, strengthening cancer research and patient-centered innovation in Louisiana. He will establish a research program focused on nuclear medicine and dedicate time to direct patient care through a clinical partnership.
This study found a decline in racial and ethnic disparities in receipt of ERBB2-targeted therapies among older Medicare beneficiaries with ERBB2-positive breast cancer. The narrowing of disparities may be attributed to changes in healthcare practices or policies over time.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
Researchers at Karolinska Institutet have identified new biomarkers in urine that can indicate the presence and severity of prostate cancer with high precision. The findings surpass current blood biomarker PSA in terms of diagnostic accuracy.
A phase II trial found that PD-1 blockade with dostarlimab induced complete tumor clearance and resolved the need for surgery in patients with early-stage mismatch repair-deficient cancers. This approach showed promise for preserving organs, improving quality of life, and potentially increasing survival.
Insilico Medicine is presenting significant achievements in cancer therapy and immunology, including AI-powered discovery of potential therapies and novel solutions for unmet needs. The company's Pharma.AI platform has received IND clearance for 10 molecules, with promising results in Phase 2a clinical studies.
A cohort study found that women with screen-detected estrogen receptor–positive or human epidermal growth factor receptor 2–negative breast cancer who underwent prior screening had an earlier stage of diagnosis and lower breast cancer mortality compared to those who did not undergo prior screening.
Current computed tomography (CT) imaging may lead to up to 103,000 future cancers over a patient's lifetime. If practices persist, CT-associated cancer could account for 5% of all new diagnoses annually.
Living in disadvantaged neighborhoods is associated with a higher risk of mortality from breast cancer in Black women. Community-level interventions aimed at reducing environmental stressors and improving access to high-quality cancer care could help reduce racial disparities in breast cancer survival.
Researchers developed an IRRS model to predict prognosis and immunotherapy response in CRC patients by integrating clinical data and transcriptomic profiles. The model identified a robust multi-gene signature associated with improved survival and immune infiltration in low-risk patients.
Jeffrey E. Lee, M.D. has been appointed Chief Medical Executive at MD Anderson, succeeding Dr. Peter WT Pisters. With over 34 years of tenure, Lee will lead the institution's efforts in research, patient care, prevention, and education. He brings a strong track record of leadership and clinical expertise to the role.
A new surgical technique called NeuroSAFE has been shown to preserve erectile function in men with prostate cancer, with 39% of patients experiencing no or mild dysfunction after treatment. This is compared to 23% of those who received standard surgery.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.
A multicenter cohort study found that higher adherence to annual lung cancer screening was associated with increased overall and early-stage lung cancer detection rates. However, adherence decreased over time, suggesting it is a critical quality metric for lung cancer screening.
This cohort study found that geographic access to cancer care is associated with guideline-recommended treatment for early-stage non–small cell lung cancer. Socially marginalized patients benefited from improved treatment outcomes and prognosis when accessing care in their local area.
Impact Journals is proud to exhibit at the AACR Annual Meeting 2025, featuring its esteemed journals Aging-US, Oncotarget, Oncoscience, and Genes & Cancer. The meeting highlights significant advancements in cancer research, aligning with Impact Journals' mission to disseminate impactful scientific research.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.
Breast and colorectal cancer screening rates have recovered from pandemic-related declines, surpassing pre-pandemic estimates. Cervical cancer screening rates remain below pre-pandemic levels, indicating a persistent trend of declining early-stage diagnoses.
Cervical cancer incidence increased in rural US counties, with higher rates among white women, likely due to lower screening coverage and diagnostic care utilization. Rural areas may experience heightened access barriers, contributing to lower HPV vaccine uptake.
The ESMO Targeted Anticancer Therapies Congress 2025 features state-of-the-art presentations on new targets, tumour-agnostic drug development, and the role of artificial intelligence in cancer treatment. The congress also highlights recent study results and their potential impact on precision medicine.
A recent study found that Medicare decedents with advanced cancer often receive aggressive care at the end of life, despite a lack of support. The study highlights the need for improved quality of care and more comprehensive approaches to address this issue.
Cancer cells work together to source nutrients from their environment, a cooperative process that can be targeted for treating cancer. Researchers identified key enzymes and mechanisms behind this cooperation, including the enzyme CNDP2, which can be inhibited by the drug bestatin.
The joint venture will unite the nation's largest comprehensive pediatric system with a top pediatric cancer program and the nation's leading comprehensive cancer center. The collaboration aims to accelerate improved outcomes for patients in Texas and around the world, increasing access to clinical trials and innovative treatments.
A cross-sectional study found that perceived stress, inadequate social support, racial discrimination, and neighborhood deprivation negatively impacted systemic and tumor immunity in Black women. These findings may inform prevention and public health interventions for cancer health disparities.
Research teams have made significant breakthroughs in understanding cancer mechanisms, including the role of genetic mutations and tumor microenvironment interactions. These findings hold promise for developing targeted therapies and improving cancer treatment outcomes.
Researchers from Notre Dame and a Mexican hospital created a cooperative cancer monitoring tool to track children's health in low-income communities. The SaludConectaMX system aims to alleviate the challenges faced by families with pediatric cancer, including fragmented healthcare systems and limited access to resources.
Researchers developed a method to detect H3K27M-mutant droplets from circulating tumor DNA in cerebrospinal fluid, enabling early diagnosis and treatment of leptomeningeal disease. This approach improved survival rates for patients with diffuse midline gliomas.
Scientists from Gladstone Institutes developed a new method called RASAM, which made a surprising discovery that large sections of newly formed DNA are hyperaccessible for many hours. This finding holds important implications for basic understanding of biology and the development of new medicines.
Jeremy L. Davis, MD, has been appointed as the new Surgical Oncology Lead for UMGCCC and Chief of the Division of Surgical Oncology in the Department of Surgery at UMSOM. Dr. Davis is a nationally recognized surgical oncologist with expertise in gastric cancer research.
A new study published in Cell reveals significant differences in the immune response of children and adults to cancer, with potential implications for targeted therapies. The research shows that children's tumours are generally less inflammatory and have fewer mutations, making them appear less foreign to their immune system.
According to UTHealth Houston research, adolescent and young adult men with cancer have a slightly elevated risk of having preterm birth and children with low birth weight. However, the likelihood of live birth was highest for fathers who had thyroid cancer and lowest for those with gastrointestinal cancer.
A nationwide cohort study in Korea found that postdiagnosis weight gain is associated with an increased risk of heart failure after breast cancer development. Effective weight intervention can protect cardiovascular health, particularly within the first few years after diagnosis.
A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.
A new study published in Nature Medicine shows that AI-based models can accurately identify ovarian cancer in ultrasound images, achieving an accuracy rate of 86.3%. The models also reduce the need for expert referrals and misdiagnosis rates by 63% and 18%, respectively.
A cohort study found a decrease in localized invasive breast cancer and regional invasive breast cancer since the 2009 guideline changes, but no decrease in advanced cancer stages. Further research is needed to understand these trends.
A recent study found that nearly two-fifths of women aged 40-49 did not receive biennial mammography screening, highlighting significant gaps in early detection. To optimize breast cancer detection, ensuring equitable adherence to U.S. Preventive Services Task Force recommendations is crucial.
Researchers discovered a novel vulnerability in prostate cancer cells that starves them of critical nutrients called amino acids. By inhibiting two proteins, GCN2 and p53, the team found a way to effectively destroy prostate tumors.
Researchers identified YTHDF2 as a key player in advancing blood cancers, which can help cancer cells evade immune system detection. A new compound CCI-38 targets and suppresses YTHDF2, reducing aggressive blood cancer growth.
A randomized clinical trial found that cannabidiol (CBD) significantly reduced anxiety levels 2-4 hours after ingestion in women with advanced breast cancer. CBD's anxiolytic effect suggests its potential as a treatment for scan-related anxiety.
Adding camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response in patients with early or locally advanced triple-negative breast cancer. The treatment showed substantial benefits, leading researchers to explore its potential as a neoadjuvant strategy.
A randomized study found that active monitoring for low-risk ductal carcinoma in situ did not increase invasive cancer risk compared to guideline-concordant care. Women on active monitoring had comparable rates of disease recurrence and survival.
Women with low-risk ductal carcinoma in situ reported similar experiences undergoing active monitoring versus guideline-concordant care. The study found that both approaches had comparable lived experiences during the 2-year follow-up period.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.